Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Many people in the US with chronic hepatitis B not being properly monitored

Many people with chronic hepatitis B virus infection have infrequent medical monitoring, according to US research published in the online edition of Clinical Infectious Diseases. Analysis of the

Published
6 hours ago
By
Michael Carter
Neglect of infectious diseases in prisons highlighted at AIDS 2016

“Prisoners are among the most neglected of the key populations; they bear higher burdens of HIV, viral hepatitis and tuberculosis than in the communities from which they

Published
25 August 2016
By
Theo Smart
HIV not a risk factor for fibrosis progression in people with hepatitis C

HIV co-infection is not associated with accelerated progression of liver fibrosis in people with hepatitis C virus (HCV) infection, according to US research published in the online edition

Published
24 August 2016
By
Michael Carter
Hillary Clinton calls out drug maker Gilead over price of hepatitis C pills

Democratic presidential nominee Hillary Clinton said Wednesday her administration will go after drug companies that charge exorbitant prices, singling out the company Gilead, whose hepatitis C drugs cost between $900 and $1,000 per pill in the United States.

Published
19 August 2016
From
UPI.com
Nottinghamshire dentist Desmond D'Mello struck off by General Dental Council

A dentist who sparked "the biggest NHS patient recall in history" is struck off.

Published
19 August 2016
From
BBC Health
German agency criticises European programme for speeding some drug approvals

In pointed remarks, Germany’s cost-effectiveness watchdog has criticised an effort by European regulators to accelerate approval for new medicines by limiting its requirements for evidence. The concerns raised by the agency come as regulators on both side of the Atlantic increasingly look to such approaches to get new drugs to patients with unmet medical needs. At issue is a proposal called adaptive pathways, a term used to describe a method for jumpstarting drug approvals for select patient populations. Two years ago,an EMA pilot programme was launched to compare initial data used for approval with so-called “real world” data, which is subsequently gathered after the medicines are in use.

Published
18 August 2016
From
STAT
Ongoing hepatitis B virus replication associated with higher mortality for people with HIV

People with HIV and hepatitis B virus (HBV) co-infection have more than double the risk of death if they have ongoing high-level HBV replication, indicating a need for

Published
16 August 2016
By
Liz Highleyman
New research supports the removal of drug use as a restriction to hepatitis C treatment

New, highly curative hepatitis C therapy is both safe and effective as a treatment option for people who inject drugs receiving opioid substitution therapy according to the results of a world-first clinical trial led by Professor Gregory Dore at the Kirby Institute at UNSW Australia and published today in the Annals of Internal Medicine.

Published
15 August 2016
From
EurekAlert
AbbVie 3D and 2D hepatitis C combos work well for people with HIV and HCV co-infection

AbbVie's paritaprevir-based 3D regimen for hepatitis C virus (HCV) genotype 1 and 2D regimen for genotype 4 were shown to be highly effective and well tolerated for

Published
05 August 2016
By
Liz Highleyman
European Commission Grants Marketing Authorisation for MSD’s ZEPATIER™ (elbasvir/grazoprevir) for the Treatment of Chronic Hepatitis C Infection

MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (MRK)) today announced that the European Commission has approved ZEPATIER™ (elbasvir/grazoprevir) with or without ribavirin (RBV) for the treatment of chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection in adults.

Published
02 August 2016
From
MSD press release
← First12345...204Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close